h

Jodie Morrison, Venture Partner

Jodie Morrison is a venture partner and focuses on identifying and building transformative biotechnology companies.

Jodie is an accomplished executive and board member with experience from start up through mid-size public biotech and pharmaceuticals. Her most recent operating role was chief executive officer of Cadent Therapeutics where she led the growth of the company from early-stage clinical trails through the successful acquisition by Novartis in 2021. Prior to Cadent, Jodie served as interim chief executive officer at Keryx Biopharmaceuticals, Inc. (leading the successful merger with Akebia Therapeutics) and acting chief operating officer at Syntimmune (acquired by Alexion).  Prior to Syntimmune she served as president and chief executive officer of Tokai Pharmaceuticals, Inc. (led IPO in 2014 and merger in 2016) and held other senior positions including chief operating officer and VP/head of clinical and program operations. Prior to joining Tokai, Jodie held roles in clinical operations and medical affairs at Dyax Corporation, Curis, Inc., and Diacrin, Inc.

Jodie currently serves as Chair of the Ribon Therapeutics board and sits on the Board of Aileron Therapeutics (NASDAQ: ALRN). She previously served on the Cadent board and the pre/post-merger boards for Keryx/Akebia Biopharmaceuticals and Tokai/Novus Pharmaceuticals. Additionally, she serves on the key advisory board for Harvard Business School’s Blavatnik Fellowship in Life Science Entrepreneurship.

Jodie has been awarded the Boston Business Journal’s “Power 50” and “Women to Watch” awards and WEST’s “Making a Difference” award. Jodie’s efforts coordinating the biotech community around COVID-response via the CEO Forum she formed were written about by STAT, WSJ and WSJ Venture. In addition, Jodie has written for the CEO corner in Life Science Leaders and for the From the Trenches series of LifeSciVC.com. Her efforts as a long-time advocate for the industry around Diversity and Inclusion have included serving as a founding member of the Gender Diversity initiative at MassBio, a contributing author of a 2016 industry open letter and current work through the CEO Forum to pivot efforts towards Community Impact focused on these topics.

Jodie received her business training through the GBEP program at the MIT Sloan School of Management, her clinical research certification from Boston University School of Medicine and her B.A. magna laude in neuroscience from Mount Holyoke College.

In her spare time, Jodie enjoys adventure travel and hiking with her family and awesome dog Ruby.